| Name | Company | P/L % | MPV |
|
|---|---|---|---|---|
| Lord Glendonbrook |
|
Stryker / NYQ:SYK | 344.89% | £311,420.35 |
| Lord Glendonbrook |
|
Abbott Laboratories / NYQ:ABT | 252.92% | £247,044.79 |
| Lord Sassoon |
|
Abbott Laboratories / NYQ:ABT | 171.03% | £189,723.39 |
| Lord Grabiner |
|
Boston Scientific / NYQ:BSX | 138.22% | £166,757.37** |
| Baroness Noakes |
|
Smith & Nephew / NYQ:SNN | 47.28% | £103,096.26 |
| Lord Glendonbrook |
|
Smith & Nephew / NYQ:SNN | 36.70% | £95,686.62 |
| Lord Mance |
|
Stryker / NYQ:SYK | 12.31% | £78,613.82 |
| Lord Glendonbrook |
|
Medtronic / NYQ:MDT | 10.66% | £77,463.33** |
| Lord Howard of Rising |
|
Ekf Diagnostics / LSE:EKF.L | -0.84% | £69,411.68 |
| Lord Londesborough |
|
Abbott Laboratories / NYQ:ABT | -18.06% | £57,359.86 |
| Lord Sassoon |
|
Medtronic / NYQ:MDT | -20.36% | £55,745.76 |
| Lord Glendonbrook |
|
Align Technology / NMS:ALGN | -37.72% | £43,598.17 |
| Lord Kakkar | Cyte / NMS:CTKB | -55.35% | £31,251.50** | |
| Lord Browne of Madingley | Allurion / NYQ:ALUR | -74.92% | £17,552.87 |